Helicobacter Pylori infection in systemic sclerosis and its association with upper gastrointestinal dysfunction by Chilukuri Balaji, Mahendran Bhuvanesh, Chinnadurai Saranya, Ramamoorthy Ramesh, Mayilsamy Saravanan, Sankaralingam Rajeswari

“…Anti-H. pylori IgG antibody levels showed no correlation with disease duration, erythrocyte sedimentation rate, C-reactive protein, interstitial lung disease, and modified Rodnan Skin Score. …”
Get full text

TRAIL-Dependent Resolution of Pulmonary Fibrosis by David M. Habiel, Ana Paula Moreira, Ugur B. Ismailoglu, Michael P. Dunleavy, Karen A. Cavassani, Nico van Rooijen, Ana Lucia Coelho, Cory M. Hogaboam

“…Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. …”
Get full text

Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report by Tomoki Kozono, Kentaro Tanaka, Tomoko Yagi, Kazuto Kamikawaji, Masaki Watanabe, Azusa Iwanaga, Minako Hamada, Yoshifusa Koreeda, Hiromasa Inoue, Ikkou Higashimoto

“…APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease–associated interstitial lung disease (ILD). Here, we describe a rare case of a patient with systemic sclerosis who was diagnosed with APAP after the exacerbation of lung opacities during treatment with immunosuppressive agents. …”
Get full text

Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease by Natalie K. Kozij, John T. Granton, Philip E. Silkoff, John Thenganatt, Shobha Chakravorty, Sindhu R. Johnson

“…Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of differences across lung diseases, disease-subsets (SSc, systemic lupus erythematosus), and healthy-controls. …”
Get full text

Quality of life in idiopathic pulmonary fibrosis in Latin American countries by H. Aguilar-Duran, M. Fernández, M. González-García, E. Rincón-Alvarez, M. Alberti, F. Caro, E. Tavera, E. Vásquez, N. Cortez, M. Salinas, M. Florenzano, C. Florestano, Ivette Buendia-Roldan

“…Abstract Background Idiopathic pulmonary fibrosis (IPF) is the most common Interstitial Lung Disease (ILD). It is characterized by dyspnoea and a progressive decline in lung function, which negatively affects life. …”
Get full text

Significance of N-terminal pro-B-type natriuretic peptide levels in lung cancer by Sinem İnan, Semra Bilaçeroğlu, Burcu Uludağ Artun

“…A total of 105 lung cancer and 120 control patients (chronic obstructive lung disease, interstitial lung disease, pulmonary thromboembolism, and pneumonia; 30/subgroup) with measured NT-proBNP levels were included retrospectively. …”
Get full text

Profiles of systemic lupus erythematosus patients with co-existing sickle cell disease: a coincidence or true association? by Hakeem Babatunde Olaosebikan, Etseoghena Igebu, Adebukola Khairat Orolu, Gbenga Joshua Odunlami, Ilo Azizat Bamisebi, Akin Dada, Ebele Uche, Olufemi Adelowo

“…Two are on maintenance hemodialysis, one with interstitial lung disease, and one on long-term anticoagulation due to deep vein thrombosis. …”
Get full text

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system by Ke He, Kaidi Zhao, Tingyi Yin, Meng Liu, Jiashu Liu, Wenqian Du, Xinyi Liu, Baochen Cheng, Dewu Zhang, Yan Zheng

“…Additionally, we found potential adverse reactions not noted on the drug’s label that exhibited positive signals, including depression, increased blood pressure, peripheral swelling, gait disturbance, inability to walk, stress, myocardial infarction, sepsis, uveitis, nephrolithiasis, and interstitial lung disease. Moreover, this analysis highlighted the critical need for vigilant monitoring of adverse events, especially during the first month following the initiation of treatment. …”
Get full text

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases by Kazuhiro Usui, Tomonori Ushijima, Yoshiaki Tanaka, Chiharu Tanai, Hiromichi Noda, Norifumi Abe, Hajime Horiuchi, Teruo Ishihara

“…Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended, however, the frequency of EGFR mutation in patients with ILD and the efficacy and safety of EGFR-TKI in patients with ILD and EGFR mutation are unknown. …”
Get full text

A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade by Manush Sondhi, Megan Lear, Saleha Dar, Madiha Tariq

“…Distinctive features include severe skin lesions, dysphagia, and minimal interstitial lung disease. Management focuses on early cancer detection and treatment, with options for refractory disease, including IVIg, rituximab, and emerging therapies like JAK inhibitors. …”
Get full text

Health-related Quality of Life and Exercise Capacity in Double Lung Transplant Recipients With Baseline Lung Allograft Dysfunction by Alisha Rullay, BSc, Karina Kaur, BSc, Jennifer Holman, PT, Laura C. van den Bosch, MD, Justin G. Weinkauf, MD, Jayan Nagendran, MD, PhD, Rhea A. Varughese, MD, Alim S. Hirji, MD, Dale C. Lien, MD, Jason C. Weatherald, MD, Kieran M. Halloran, MD

“…Patients with interstitial lung disease as an indication for transplant and those who received older, female, and heavy smoking donors were at increased risk of BLAD. …”
Get full text

FBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis by Yu Cheng, Yang Jiao, Wan Wei, Mengjia Kou, Yaodong Cai, Yang Li, Hao Li, Tonghua Liu

“…BackgroundIdiopathic Pulmonary Fibrosis (IPF), an interstitial lung disease of unknown etiology, remains incurable with current therapies, which fail to halt disease progression or restore lung function. …”
Get full text

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry by Christopher J. Ryerson, Benjamin Tan, Charlene D. Fell, Hélène Manganas, Shane Shapera, Shikha Mittoo, Mohsen Sadatsafavi, Teresa To, Andrea Gershon, Jolene H. Fisher, Kerri A. Johannson, Nathan Hambly, Nasreen Khalil, Theodore K. Marras, Julie Morisset, Pearce G. Wilcox, Andrew J. Halayko, Mohammad Adil Khan, Martin Kolb

“…The relative rarity and diversity of fibrotic interstitial lung disease (ILD) have made it challenging to study these diseases in single-centre cohorts. …”
Get full text

Association of combined pulmonary fibrosis and emphysema in rheumatoid arthritis with high titer of rheumatoid factor and autoimmunity to the lung by Aiping Ma, Renliang Huang, Jiaxi Guo, Guangdong Wang, Heqing Huang, Xinze Li, Shan Zhong, Yan Huang, Shaowei Lin, Yikai Lin, Qiaomiao Zhou, Susanne Krauss-Etschmann, Frank Petersen, Zhanxiang Wang, Xinhua Yu, Xinhua Yu

“…Patient IgG and IgM autoantibodies to primary human bronchial epithelial cells (HBEC) from healthy donors were assessed using flow cytometry.FindingsAmong the 976 RA patients, 414 (42.4%) developed interstitial lung disease (ILD), with 74 (7.6%) experiencing CPFE. …”
Get full text

The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled mult... by Toby M Maher, A John Simpson, Anthony Cahn, David Thickett, Luke Vale, Allan B Clark, Nazia Chaudhuri, Ian Forrest, Lisa G Spencer, Christopher Ward, Stephen Jones, Ganesh Raghu, Andrew M Wilson, Helen Parfrey, Megan Jones, Matthew Hammond, Jaclyn Ann Smith, Shajahan Wahed

“…Secondary assessments include cough frequency (in a subgroup) measured using the VitaloJAK cough monitor, the King’s Brief Interstitial Lung Disease questionnaire, the Raghu Scale for Pulmonary Fibrosis, Medical Research Council dyspnoea score, EQ-5D-5L, Leicester Cough Questionnaire, modified DeMeester reflux symptoms questionnaire and opportunistically captured routine lung function measurements. …”
Get full text

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency by Anna Roppelt, Ulyana Markina, Irina Beloglazova, Irina Beloglazova, Vasily Parshin, Dmitry Kanner, Dmitry Pershin, Mariia Fadeeva, Elena Raykina, Maxim Aleksenko, Alexander Karaulov, Mariana Lysenko, Mariana Lysenko, Daria Fomina, Daria Fomina, Daria Fomina

“…We report on a 32-year-old male patient with interstitial lung disease, cytopenia, and lymphadenopathy accompanied by de-novo deletion in PTPN2. …”
Get full text

Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis by Lu Cheng, Lu Cheng, Yanhong Li, Yu Zhou, Yingying Ling, Tong Wu, Zongan Liang, Yinlan Wu, Chunyu Tan, Yi Liu, Yong Zhang

“…These changes in the levels of intact N-glycopeptides are associated with various aspects of SSc, including diffuse SSc (dSSc), interstitial lung disease (ILD), disease progression, cardiovascular involvement and C-reactive protein in the peripheral blood. …”
Get full text

The Pathogenic Role of Expanded CD8⁺CD28^null Angiogenic T Cells in ANCA-Associated Vasculitis by Haomiao Shen, Jinlin Miao, Haoyang Sun, Kui Zhang, Renli Liu, Zichao Li, Leyang Zhang, Peiyan Zhang, Jiawei Wang, Bei Zhang, Longyu Chen, Zhaohui Zheng, Ping Zhu

“…<b>Results</b>: CD8⁺CD28^null Tang levels were significantly higher in the peripheral blood of AAV patients compared to HCs, and their levels were further increased in AAV patients with MPO⁺, p-ANCA⁺, or interstitial lung disease compared to their respective control groups. …”
Get full text

Macrophage-Derived Biomarkers of Idiopathic Pulmonary Fibrosis by E. Bargagli, A. Prasse, C. Olivieri, J. Muller-Quernheim, P. Rottoli

“…Biomarker discovery and clinical application are a recent topic of interest in the field of interstitial lung diseases (ILDs). Cytokines, CC-chemokines, and other macrophage-produced mediators are the most promising prognostic biomarkers. …”
Get full text

Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives by Giuseppe Lopalco, Luca Cantarini, Antonio Vitale, Florenzo Iannone, Maria Grazia Anelli, Laura Andreozzi, Giovanni Lapadula, Mauro Galeazzi, Donato Rigante

“…An overview of monogenic autoinflammatory disorders, PFAPA syndrome, rheumatoid arthritis, type 2 diabetes mellitus, uveitis, pericarditis, Behçet’s disease, gout, Sjögren’s syndrome, interstitial lung diseases, and Still’s disease is presented to highlight the fundamental points that interleukin-1 displays in the cryptic interplay between innate and adaptive immune systems.…”
Get full text